Sopharma AD ended its most successful financial year after the crisis. 2017 ended with 12.5% revenue growth reaching 205.3 million BGN, 44.8% increase in operating profit, 30.7% EBITDA growth and almost 10% growth in net profit.
During this successful year, the company took two important investment decisions, namely to start the construction of:
1. An extraction plant in Kazanlak, which will allow more effective and modern production of all phyto products and
2. A new lyophilic plant in Sofia, a necessary step for increasing the production capacity for the life-saving Methylprednisolone.
After nearly five years of low investment activity these projects are a logical continuation of the company's sustainable development program and our well-recognized social function in the healthcare sector in Bulgaria.